Keyword: Olivier Brandicourt

Dupixent grew sales by 28% sequentially at constant currencies, to €225 million, and that doesn't even count a recent major approval in asthma.

Dieter Weinand, Bayer’s head of the pharma division, will join Sanofi to lead a newly formed primary care unit, while Sanofi's Stefan Oelrich will take his post.

Sanofi and the Securities and Exchange Commission entered a $25 million civil settlement over bribery allegations in the Middle East.

Sanofi's CFO search lasted two months and led the company to a financial executive from French automaker PSA Group.

Sanofi posted strong vaccines growth last year, but the first quarter of 2018 didn't deliver quite so well.

Formulary shutouts were already hurting Sanofi's diabetes numbers. But price cuts and Medicare compounded the pain in the first quarter of 2017.

Jérôme Contamine, Sanofi's CFO for nearly a decade, plans to step down later this year after a transition period.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

At €350 million, Sanofi's new Canadian vaccine plant will be one of the largest investments ever by the company in a single facility.

Sanofi is out another potential buyer for its European generics business as India-based Torrent Pharma exited deal talks, according to a report.